GnRH receptor antagonist

January 12, 2021January 12, 2021

Orgovyx Now Available in US for Advanced Prostate Cancer

News

A couple of weeks after its approval, Orgovyx (relugolix) is now commercially available in the U.S. for adults with advanced prostate cancer through authorized specialty distributors, the therapy’s developer, Myovant ... Read more

June 25, 2020June 25, 2020

Relugolix Granted FDA Priority Review as New Treatment Type

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) Myovant Sciences submitted earlier this year requesting the approval of relugolix for the ... Read more

December 4, 2019December 6, 2019

Relugolix Induces Sustained Testosterone Reduction in Advanced PC, HERO Phase 3 Trial Results Show

News

Treatment with Myovant Sciences’ relugolix induces a long-lasting reduction in testosterone to castrate levels — similar to testosterone levels after medical or chemical castration — in nearly all men with ... Read more

November 14, 2018

Phase 3 Trial of Relugolix for Advanced Prostate Cancer Completes Patient Enrollment

News

A Phase 3 trial evaluating Myovant Sciences’ relugolix as a treatment for advanced prostate cancer patients who are sensitive to androgen deprivation treatments has completed patient enrollment, the company announced. The randomized ... Read more